Immunic to Participate in Investor, Scientific and Industry Conferences in June

Core Viewpoint - Immunic, Inc. is actively participating in several investor and scientific conferences in June 2025 to present its clinical pipeline and engage with investors [1][3]. Conference Participation - Immunic will present at the Jefferies Healthcare Conference from June 3-5, with CEO Daniel Vitt providing a company overview on June 5 at 4:55 pm ET [1]. - The company will also participate in the 4th RSC Anglo-Nordic Medicinal Chemistry Symposium from June 10-13, where preclinical data on antiviral candidates will be presented [1][3]. - Attendance at the UBS Life Sciences Conference in London is scheduled for June 11, with opportunities for one-on-one meetings [1]. - Immunic's management will engage in partnering activities at the BIO International Convention from June 16-19 in Boston [1]. - The 11th Congress of the European Academy of Neurology will take place from June 21-24 in Helsinki, where data on vidofludimus calcium will be presented [1][3]. - The Accelerating Bio-Innovation Conference will be attended by Dr. Vitt and Mr. Tardio from June 23-25 in Cambridge, MA [1]. Company Overview - Immunic, Inc. focuses on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases [3]. - The lead program, vidofludimus calcium (IMU-838), is in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026 [4]. - Vidofludimus calcium acts as a first-in-class nuclear receptor related 1 (Nurr1) activator, providing neuroprotective effects and anti-inflammatory properties [4]. - Other candidates include IMU-856, targeting Sirtuin 6 (SIRT6) for gastrointestinal diseases, and IMU-381, currently in preclinical testing [4].